If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-02. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Since the 1980s, spice heat has been assessed quantitatively by high-performance liquid chromatography (HPLC), which measures the concentration of heat-producing capsaicinoids, typically with capsaicin content as the main measure. As stated in one review "the most reliable, rapid, and efficient method to identify and quantify capsaicinoids is HPLC; the results of which can be converted to Scoville heat units by multiplying the parts-per-million by 16." HPLC method gives results in American Spice Trade Association 1985 "pungency units", which are defined as one part capsaicin equivalent per million parts dried pepper mass. This "parts per million of heat" (ppmH) is found with the following calculation:
=== Evolution of plant morphology === Transcription factors and transcriptional regulatory networks play key roles in plant morphogenesis and their evolution. During plant landing, many novel transcription factor families emerged and are preferentially wired into the networks of multicellular development, reproduction, and organ development, contributing to more complex morphogenesis of land plants.
Latent autoimmune diabetes in adults (LADA) is an autoimmune disease with gradual or slow destruction of pancreatic beta cells (β-cells). It is a form of type 1 diabetes (T1D) that manifests in adulthood, rather than childhood or adolescence. Due to the adult onset of LADA, as well as the relative preservation of insulin secretion at diagnosis and its slower rate of progression compared to classic T1D, LADA is often misdiagnosed as type 2 diabetes mellitus (T2D) which is a metabolic disorder rather than an autoimmune disease. The concept of LADA was first introduced in 1993. Though sometimes colloquially referred to as "type 1.5 diabetes" due to its sharing some clinical and metabolic characteristics of both T1D and T2D, LADA is strictly defined under the rubric of T1D by the American Diabetes Association (ADA) as an autoimmune form of diabetes. Most individuals with LADA have circulating islet autoantibodies which are indicative of progressive β-cell loss and may help predict the rate of disease progression. Misdiagnosis of LADA can lead to inappropriate treatment, as patients may be managed as having T2D rather than their underlying autoimmune condition.
== Function == Actin's primary role in the cell is to form linear polymers called microfilaments that serve various functions in the cell's structure, trafficking networks, migration, and replication. The multifaceted role of actin relies on a few of the microfilaments' properties: First, the formation of actin filaments is reversible, and their function often involves undergoing rapid polymerization and depolymerization. Second, microfilaments are polarized – i.e. the two ends of a filament are distinct from one another. Third, actin filaments can bind to many other proteins, which together help modify and organize microfilaments for their diverse functions. In most cells actin filaments form larger-scale networks which are essential for many key functions:
Newer developments seek to merge aspects of FastPP and CETSA approaches, by assessing the ligand-dependent dependent proteolytic protection of targets in cells using mass spectroscopy (MS) to detect shifts in proteolysis patterns associated with protein stabilization. Present implementations still require a priori knowledge of expected targets to facilitate data analysis, but improvements in MS data collection strategies, together with the use of improved computational tools and database structures can potentially allow the approach to be used for de novo target decryption on the total cell proteome scale. This would be a major advance for drug discovery since it would allow the identification of discrete molecular targets (as well as off-target interactions) for drugs identified through high-content cellular or phenotypic drug screens.
Sources: en.wikipedia.org
=== Matsuda === The Matsuda geometry consists of an 85° electric sector, a quadrupole lens and a 72.5° magnetic sector of the same curvature direction. This geometry is used in the SHRIMP and Panorama (gas source, high-resolution, multicollector to measure isotopologues in geochemistry).
== History == In June 1959, several American pharmacologists convened at Wayne State University in Detroit to discuss a newly discovered structural analogue of meprobamate. The substitution of one hydrogen atom with an isopropyl group on one of the carbamyl nitrogens was intended to yield a drug with new pharmacological properties. It had been developed by Frank Berger at Wallace Laboratories and was named carisoprodol. Building on meprobamate's pharmacological effects, carisoprodol was intended to have better muscle relaxing properties, less potential for addiction, and a lower risk of overdose. Carisoprodol's effect profile did indeed turn out to differ significantly with respect to meprobamate, with carisoprodol possessing stronger muscle relaxant and analgesic effects.
== Awards and honors == Wadden has received recognition from professional societies and universities throughout his career. Early honors included the President’s New Researcher Award from the Association for the Advancement of Behavior Therapy (1986). He was later elected a Fellow of the Academy of Behavioral Medicine Research (1992), Society of Behavioral Medicine (1995), College of Physicians of Philadelphia (2000), and the Obesity Society (2002). Subsequent honors included the Distinguished Alumni Award from the University of North Carolina at Chapel Hill (2007), the Arthur K. Asbury Outstanding Faculty Mentor Award from the University of Pennsylvania (2007), the George A. Bray Founder's Award (2009), and the TOPS Research Achievement Award (2012), both from the Obesity Society. Other honors included the Bud Orgel Award for Distinguished Achievement in Research (2012) and the inaugural Thomas A. Wadden Award for Distinguished Mentorship from The Obesity Society (2015). Later recognitions included an honorary Doctor of Humane Letters from the Philadelphia College of Osteopathic Medicine (2019), designation as a “distinguished leader in obesity medicine” by the American Board of Obesity Medicine (2021), the Friends of Albert (Mickey) Stunkard Lifetime Achievement Award from The Obesity Society (2022), and the George Bray Outstanding Achievements Award in Obesity Research from the American Society for Nutrition (2025).
== Classification of MMC == MMC can be classified into physical MMC and chemical MMC. In the former method, the stationary phase is constructed of two or more types of packing materials. In the chemical method, just one type of packing material containing two or more functionalities is used.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.